Market Potential | Analysts project $10-$20 price targets, reflecting optimism about SGT-003's potential in the $2.5B-$3B DMD market and upcoming regulatory milestones |
Technological Edge | Delve into Solid's proprietary AAV-SLB101 capsid technology, offering enhanced muscle targeting and superior manufacturing capabilities as key differentiators |
Pipeline Expansion | Explore Solid's strategic move into Friedreich's Ataxia and CPVT, leveraging gene therapy expertise to address high unmet needs in rare genetic disorders |
DMD Gene Therapy | Solid Biosciences' SGT-003 shows promising early results for Duchenne muscular dystrophy, with potentially best-in-class microdystrophin expression and clean safety profile |
Metrics to compare | SLDB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLDBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | −2.4x | −0.6x | |
PEG Ratio | −0.12 | −0.09 | 0.00 | |
Price / Book | 3.9x | 2.4x | 2.6x | |
Price / LTM Sales | - | 9.3x | 3.2x | |
Upside (Analyst Target) | 122.2% | 181.5% | 48.1% | |
Fair Value Upside | Unlock | 17.1% | 5.8% | Unlock |
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.